Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?
2013 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 33, no 3, 1009-1011 p.Article in journal (Refereed) Published
Aim: To answer the questions: Is the α/β ratio (radiosensitivity to size of dose-per-fraction) really low enough to justify using a few large dose fractions instead of the traditional many small doses? Does this parameter vary with prognostic risk factors? Methods and Materials: Three large statistical overviews are critiqued, with results for 5,000, 6,000 and 14,000 patients with prostate carcinoma, respectively. Results: These major analyses agree in finding the average α/β ratio to be less than 2 Gy: 1.55 (95% confidence interval=0.46-4.52), 1.4 (0.9-2.2), and the third analysis 1.7 (1.4-2.2) by ASTRO and 1.6 (1.2-2.2) by Phoenix criteria. All agree that α/β values do not vary significantly with the low, intermediate, high and “all included” risk factors. Conclusion: The high sensitivity to dose-per-fraction is an intrinsic property of prostate carcinomas and this supports the use of hypofractionation to increase the therapeutic gain for these tumours with dose-volume modelling to reduce the risk of late complications in rectum and bladder.
Place, publisher, year, edition, pages
International Institute of Anticancer Research (IIAR) , 2013. Vol. 33, no 3, 1009-1011 p.
Prostate cancer, radiation therapy, alpha/beta, LQ model
Cancer and Oncology
IdentifiersURN: urn:nbn:se:liu:diva-91554ISI: 000316770400034OAI: oai:DiVA.org:liu-91554DiVA: diva2:618284